Teleflex FY2026 EPS Estimate Decreased by Zacks Research

Teleflex Incorporated (NYSE:TFX) – Stock analysts at Zacks Research lowered their FY2026 EPS estimates for Teleflex in a research report issued on Monday, December 15th. Zacks Research analyst Team now expects that the medical technology company will earn $14.90 per share for the year, down from their previous estimate of $14.92. Zacks Research currently has a “Hold” rating on the stock. The consensus estimate for Teleflex’s current full-year earnings is $13.98 per share. Zacks Research also issued estimates for Teleflex’s Q2 2027 earnings at $4.08 EPS and FY2027 earnings at $16.36 EPS.

Teleflex (NYSE:TFX) last posted its quarterly earnings data on Thursday, November 6th. The medical technology company reported $3.67 EPS for the quarter, topping the consensus estimate of $3.38 by $0.29. Teleflex had a negative net margin of 10.28% and a positive return on equity of 15.64%. The firm had revenue of $892.90 million during the quarter, compared to analyst estimates of $892.79 million. During the same quarter in the previous year, the business posted $3.49 EPS. Teleflex’s revenue was up 19.4% on a year-over-year basis. Teleflex has set its FY 2025 guidance at 14.000-14.200 EPS.

Other analysts have also recently issued research reports about the company. Needham & Company LLC reissued a “hold” rating on shares of Teleflex in a research report on Tuesday, December 9th. Truist Financial decreased their price target on Teleflex from $128.00 to $120.00 and set a “hold” rating for the company in a research note on Monday, November 10th. Wells Fargo & Company raised their price target on Teleflex from $114.00 to $139.00 and gave the stock an “equal weight” rating in a report on Wednesday, December 10th. Weiss Ratings restated a “sell (d)” rating on shares of Teleflex in a research note on Monday. Finally, Wall Street Zen lowered shares of Teleflex from a “buy” rating to a “hold” rating in a research report on Saturday, November 15th. One investment analyst has rated the stock with a Buy rating, nine have assigned a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, Teleflex currently has a consensus rating of “Reduce” and a consensus target price of $140.29.

Teleflex Price Performance

NYSE TFX opened at $125.19 on Thursday. The firm’s fifty day simple moving average is $120.09 and its two-hundred day simple moving average is $121.00. The firm has a market capitalization of $5.53 billion, a P/E ratio of -17.03, a P/E/G ratio of 1.49 and a beta of 0.95. The company has a current ratio of 2.57, a quick ratio of 1.53 and a debt-to-equity ratio of 0.67. Teleflex has a 12-month low of $102.58 and a 12-month high of $185.94.

Teleflex Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Monday, December 15th. Shareholders of record on Friday, November 14th were given a dividend of $0.34 per share. The ex-dividend date of this dividend was Friday, November 14th. This represents a $1.36 dividend on an annualized basis and a yield of 1.1%. Teleflex’s dividend payout ratio (DPR) is currently -18.50%.

Institutional Trading of Teleflex

Several large investors have recently made changes to their positions in the business. Thurston Springer Miller Herd & Titak Inc. raised its holdings in shares of Teleflex by 242.9% during the second quarter. Thurston Springer Miller Herd & Titak Inc. now owns 216 shares of the medical technology company’s stock worth $26,000 after purchasing an additional 153 shares during the last quarter. MassMutual Private Wealth & Trust FSB boosted its holdings in Teleflex by 57.9% in the third quarter. MassMutual Private Wealth & Trust FSB now owns 210 shares of the medical technology company’s stock valued at $26,000 after purchasing an additional 77 shares during the last quarter. Brooklyn Investment Group grew its position in Teleflex by 258.6% during the 1st quarter. Brooklyn Investment Group now owns 208 shares of the medical technology company’s stock worth $29,000 after purchasing an additional 150 shares during the period. Hantz Financial Services Inc. grew its position in Teleflex by 248.8% during the 3rd quarter. Hantz Financial Services Inc. now owns 279 shares of the medical technology company’s stock worth $34,000 after purchasing an additional 199 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. purchased a new position in shares of Teleflex during the 3rd quarter valued at about $35,000. 95.62% of the stock is owned by hedge funds and other institutional investors.

Teleflex Company Profile

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.